Neuronetics (STIM) Q2 2026 Earnings Call Transcript
Neuronetics (STIM) reported Q2 2026 revenue of $41.6M, up 9.1% YoY. Greenbrook revenue grew 16.8% YoY, while NeuroStar revenue fell 2.7% YoY. Net loss narrowed to $3.4M. Full-year revenue guidance was set at $160M-$164M, with gross margin guidance raised to 48%-50%. The company expanded NeuroStar acquisition options and integrated AI into operations. Management highlighted growth opportunities in psychedelic-based therapies and strategic collaborations.
How this was made
The 30-second read
Why it matters
The most tradable elements are the updated full-year revenue and gross margin ranges, the cash flow outlook, and management’s caution that second-half revenue may be choppy due to new commercial options.
Market read
Traders can reprice STIM based on the guidance update (narrowed revenue range, higher gross margin) while monitoring cash burn and execution risk from commercial model changes.
What to watch
Cash flow remains negative for the full year and clinic capacity is still ~40% unused, so investors may focus on whether utilization ramps fast enough to offset ongoing operating cash burn.
Background
This is a transcript-style summary of Neuronetics’ Q2 2026 financial and operating results call, including guidance and commercial model updates.
Ticker impact
Neuronetics reported Q2 2026 results and updated full-year guidance, including revenue $160M-$164M and gross margin 48%-50%.
Likely supportive for shares versus prior range, but tempered by negative cash flow guidance and “choppier” second-half revenue risk.
The article discloses multiple decision-relevant datapoints: Q2 revenue growth, gross margin improvement, narrowed FY revenue and GM ranges, and cash flow guidance remaining negative. It also flags execution risk from commercial model transitions, which can limit upside follow-through.
Market effects
Reinforces demand and unit economics narrative for neurostimulation and clinic-network operators, with emphasis on commercial model mix shifts.
No specific regional impact disclosed beyond clinic network utilization and capacity utilization.
Primarily US-focused clinic and reimbursement dynamics; no international expansion details provided.
Counterpoint
Higher gross margin and revenue growth may be partly mix-driven during a commercial transition, so durability into the second half could be weaker than guidance implies.
Key entities
- companyNeuronetics
STIM, reported Q2 2026 results and updated FY 2026 guidance, including revenue and gross margin ranges.
- executiveDan Reuvers
CEO who discussed commercial model transition and second-half revenue volatility risk.
- executiveNir Naor
CFO appointed recently, discussed financial outlook and prior experience.
- partnerCompass Pathways
Mentioned for collaboration on psychedelic-based therapies using existing clinic infrastructure.
- partnerANT Neuro
Mentioned as providing FDA-cleared neuronavigation technology for NeuroStar customers.
